Featured Article
Patients need full access to all PH treatments, advocates tell ICER
Pulmonary hypertension advocates recently participated in an Institute for Clinical and Economic Review meeting about a new PH treatment expected to receive FDA approval in March. The advocates shared scientific information and personal insight about the impact of PH, the importance of robust insurance coverage for treatment and benefits of the new drug, sotatercept.